EULAR 2020: Phase 2 clinical trial sifted at the persistence of JAK1 oral inhibitor Filgotinib in psoriasis arthritis
Last Update: 2020-06-16
Search more information of high quality chemicals, good prices and reliable suppliers, visit
At the 2020 Annual Meeting of the European Union of Rheumatology (EULAR 2020), Gliead Sciences announced data from its phase 2 STUDY of THE UBL1 inhibitor filgotinib for the treatment of psoriasis arthritis (PsA) and the EQUATOR-2 studyThe results showed that filgotinib had long-lasting efficacy and consistent safety in active PsA patientsDr Mark Genovese, Senior Vice President of Inflammation, said: "Despite treatments in place, patients with psoriasis still face challenging long-term symptoms, including joint swelling, stiffness, pain and fatigue, all of which can seriously affect their daily livesThe results from the EQUATOR study project showed that PsA patients treated with filgotinib received an ongoing responseWe look forward to advancing the key Phase 3 PENGUIN clinical trial program to confirm the safety and efficacy of filgotinib as a potential treatment option for the diseaseThe efficacy and safety of Filgotinib in patients with active PsA: The subgroup analysis of the phase 2 trial (EQUATOR) of a randomized, placebo-controlled trial (POSTER?0343) was statistically significant compared to the placebo in the Filgotinib treatment groupThe activity index (DAPSA) of psoriasis arthritis disease also reached statistical significance in most subgroups treated by filgotinibThere were no clinically relevant differences when comparing the responses of subgroups to filgotinibFilgotinib showed consistent security, and no new security issues were found in the studyLong-term efficacy of Filgotinib in PsA: An interim analysis conducted at week 52 by the Open Label Extension Study (EQUATOR-2) (Poster?0339) showed that in patients with active PsA, multiple disease activities and therapeutic response indicators showed that Filgotinib had a sustained effectIn the initial EQUATOR trial, most patients with minimal disease activity (MDA) and ACR50 response maintained MDA and ACR50 at week 52, and some PATIENT seno-reresponders achieved an responseIn week 52, a total of 33.6% of patients achieved MDA response sanded ACR50 responses in 55.0% of patientsNo new security issues were observed
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.